Results of large cardiology‑ diabetic studies in recent years (EXAMINE, ORIGIN, SAVOR)

Česká verzia

Authors: R. Benešová ¹; M. Kvapil ²
Authors place of work: Interní klinika FNO a LF OU, Ostrava ¹; Interní klinika 2. LF UK a FN v Motole, Praha ²
Published in the journal: Kardiol Rev Int Med 2014, 16(2): 134-137
Category: Internal Medicine

Summary

Hyperglycaemia is an independent risk factor for cardiovascular morbidity and mortality. The best possible control of diabetes should therefore lead to a reduction in the incidence of cardiovascular events. To obtain approval for the new drugs it is necessary to supply clinical trial data, including information about the effect of the drug on cardiovascular risk. For gliptins that have been marketed rather recently, some studies have already been conducted that can be said to have demonstrated the safety of these drugs. However, it will still take time before we have study results that would fully satisfy the new FDA guidelines.

Keywords:
hyperglycaemia – gliptins – cardiovascular mortality and morbidity

Zdroje

1. Pelikánová T, Bartoš V. Praktická diabetologie. 4. rozšířené vyd. 2010. Praha: Maxdorf: 449– 453.

2. Green JB, Bethel MA, Paul SK et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013; 166: 983– 989.e7. doi: 10.1016/ j.ahj.2013.09.003.

3. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR‑ TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317– 1326. doi: 10.1056/ NEJMoa1307684.

4. Špinar J, Šmahelová A. SAVOR‑ TIMI 53 Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, Vnitr Lek 2013; 59: 1003– 1007.

5. White WB, Canon CP, Keller SR et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327– 1335.

6. Kvapil M. Diabetologie 2013, Praha: Triton 2013: 50– 59.